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Reduced NO levels due to the deﬁciency of tetrahydrobiopterin (BH4) contribute to impaired vasodilation in
pulmonary hypertension. Due to the chemically unstable nature of BH4, it was hypothesised that oxidatively
stable analogues of BH4 would be able to support NO synthesis to improve endothelial dysfunction in
pulmonary hypertension. Two analogues of BH4, namely 6-hydroxymethyl pterin (HMP) and 6-acetyl-7,7-
dimethyl-7,8-dihydropterin (ADDP), were evaluated for vasodilator activity on precontracted rat pulmonary
artery rings. ADDP was administered to pulmonary hypertensive rats, followed by measurement of
pulmonary vascular resistance in perfused lungs and eNOS expression by immunohistochemistry. ADDP and
HMP caused signiﬁcant relaxation in vitro in rat pulmonary arteries depleted of BH4 with a maximum
relaxation at 0.3 μM (both Pb0.05). Vasodilator activity of ADDP and HMP was completely abolished
following preincubation with the NO synthase inhibitor, L-NAME. ADDP and HMP did not alter relaxation
induced by carbachol or spermine NONOate. BH4 itself did not produce relaxation. In rats receiving ADDP
14.1 mg/kg/day, pulmonary vasodilation induced by calcium ionophore A23187 was augmented and eNOS
immunoreactivity was increased. In conclusion, ADDP and HMP are two analogues of BH4, which can act as
oxidatively stable alternatives to BH4 in causing NO-mediated vasorelaxation. Chronic treatment with ADDP
resulted in improvement of NO-mediated pulmonary artery dilation and enhanced expression of eNOS in the
pulmonary vascular endothelium. Chemically stable analogues of BH4 may be able to limit endothelial
dysfunction in the pulmonary vasculature.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Deﬁciency in NO formation has been found in patients with
primary pulmonary hypertension (Demoncheaux et al., 2005) and in
the hypoxic rat model of pulmonary hypertension (Weerackody et al.,
2009). Tetrahydrobiopterin (BH4) is an essential cofactor for nitric
oxide synthase (NOS), and mice that have very low BH4 tissue levels
exhibit pulmonary hypertension (Khoo et al., 2005), which could be
reversed by increasing BH4 through targeted transgenic overexpres-
sion of GTP cyclohydrolase 1 (GTPCH-1) (Khoo et al., 2005). Using
an experimental animal model of persistent pulmonary hypertension
of the newborn (PPHN), it was found that the oxidised form,
dihydrobiopterin (BH2) is raised in the lungs (Grobe et al., 2006). In
another animal model of PPHN, it was found that the levels of GTPCH-
1 were depressed; moreover the administration of BH4 combined
with the superoxide dismutase mimetic MnTMPyP improved pulmo-
nary artery relaxation (Nandi et al., 2006).
BH4 depletion is believed to be due to oxidative stress since SOD
overexpression restores both BH4 content and activity of GTPCH-1,
the rate-limiting enzyme in BH4 synthesis (Farrow et al., 2008). The
endothelial NO synthase (eNOS) enzyme generates superoxide when
BH4 levels decline or when it is replaced by an oxidised product, BH2
(Crabtree et al., 2009; Vasquez-Vivar et al., 2002).
In vitro administration of BH4, or its physiological precursor
sepiapterin, restored endothelium-dependent relaxation of resistance
arteries in animal models of cardiovascular disease (Pannirselvam
et al., 2003; Tiefenbacher et al., 2000) and in patients with endo-
thelium dysfunction (Heitzer et al., 2000a,b; Higashi et al., 2006;
Setoguchi et al., 2002). Since BH4 is rapidly oxidised under phys-
iological conditions, oral administration requires very high doses and
is only brieﬂy effective. Oral administration of BH4 has been reported
to improve endothelium function (Cosentino et al., 2008; Eskurza
et al., 2005) and to reduce blood markers of oxidative stress in
patients (Cosentino et al., 2008). Administration of BH4 attenuated the
rise in pulmonary artery pressure and reduced muscularisation of
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distal pulmonary arteries in rats with monocrotaline-induced pul-
monary hypertension (Francis et al., 2009).
We believe that analogues of BH4 with stable oxidative states
might be better alternatives to improve impaired relaxation associ-
ated with endothelial dysfunction and will indirectly substitute for
BH4 in the vasculature. To explore this possibility, two analogues of
BH4, namely 6-hydroxymethyl pterin (HMP) and 6-acetyl-7,7-
dimethyl-7,8-dihydropterin (ADDP), were obtained from the pro-
ducts of a large synthetic programme to generate biologically active
pteridines (Al Hassan et al., 1985).They were selected for their
chemical stability and similarity to the structure of BH4 (Suckling
et al., 2008). The tetrahydro derivative of HMP has been shown to be a
BH4 substitute (Kotsonis et al., 2001).
In the current study, we investigated the effects of these two
analogues on normal as well as BH4-depleted pulmonary arteries. We
also report in vivo administration of ADDP on endothelium-
dependent vasorelaxation in a rat model of hypoxic pulmonary
hypertension.
2. Methods
2.1. Artery ring experiments
Male Sprague–Dawley rats of body weight approximately 175–
350 g were killed by cervical dislocation. The heart and lungs were
placed in either the chilled Krebs–Henseleit solution in experiments
where normal untreated arteries were used and in chilled tissue
culture medium when the artery rings were treated to deplete the
endogenous levels of BH4. The main pulmonary artery along with its
right and left extra pulmonary branches were dissected and divided
into four rings each 2–3 mm long. Pulmonary artery rings were
mounted on to a pair of intraluminal wires under 1 g resting force in
15 ml organ baths containing oxygenated (20% O2, 5% CO2 and 75% N2
gas mixture) Krebs–Henseleit solution at 37 °C and contractile force
was measured.
Depletion of cellular BH4 was carried out using 2,4-diamino-6-
hydroxypyrimidine (DAHP), which inhibits GTPCH1, the key rate-
limiting enzyme in the synthesis of endogenous BH4 (Bagi and Koller,
2003; Kinoshita et al., 1997; Wang et al., 2008). Artery rings were
incubated for 6 h at 37 °C in minimum essential medium containing
DAHP (10−2 M) (Kinoshita et al., 1997). Control arteries received
similar incubation omitting DAHP.
In experiments showing the effects of BH4, ADDP or HMP in normal
or BH4-depleted arteries the following protocol was used. After 1 h
equilibration of the tissue, arteries were precontracted with phenyl-
ephrine: 3.6×10−8 M (the EC50 concentrations determined from
preliminary studies) followed by relaxation with 10−5 M carbachol to
check for the integrity of the endothelium. Preparations were rejected
if they did not produce a minimum of 80% relaxation to carbachol.
After washout tissues were again contracted with phenylephrine
followed by the test drugs (BH4, ADDP or HMP). One parallel ring was
used as a time control and anotherwas a vehicle control (receiving the
relevant concentrations of NH4OH present in the parallel ring treated
with ADDP or HMP). Relaxation by the drugs was measured as reduc-
tion in the percentage of precontraction obtained by phenylephrine.
To investigate if ADDP or HMP induce relaxation through NO, the
tissues after the initial contraction and relaxation with phenylephrine
and carbachol respectively were incubated with NG-nitro-L-arginine
methyl ester (L-NAME, 300 μM) for 30 min and then the effects of the
analogues were studied.
In order to investigate if ADDP or HMP elicits a protective function
on the already existing NO in the tissues, the rings were contracted
with phenylephrine and a dose–response curve to NO donor, sperm-
ine NONOate, was produced followed by washing and equilibration
for 30 min and then the rings were preconstricted with phenyleph-
rine and incubated with a single concentration of the analogues
(3×10−7 M) at which maximum relaxation was originally seen
followed by another dose–response curve to spermine NONOate.
In order to investigate the hypothesis that O2.− production might
be leading to the contraction generated by BH4, we studied the effects
of superoxide scavenger, Mn(III) tetrakis [1-methyl-4-pyridyl] por-
phyrin (MnTMPyP), on the BH4-induced contraction. Arteries were
preconstricted with phenylephrine and a concentration–response
curve to BH4 was generated. All drugs were then washed out and
MnTMPyP (30 μM) was incubated for 30 min. Previous studies per-
formed in the lab have shown that the above incubation parameters
are optimal for scavenging O2.− by MnTMPyP. Following incubation
with MnTMPyP and preconstriction with phenylephrine, a ﬁnal con-
centration response curve to BH4 was produced in the presence of
MnTMPyP.
The values are expressed as means±standard errors of means
(S.E.M.) where n= number of arterial rings from separate animals.
Statistical tests were performed using analysis of variance general
linear model (repeated measures design). Repeated measures
design was used to compare two cumulative dose response curves
generated in two different tissues. A crossover design was used to
compare two cumulative curves generated before and after they
were treated with the test drug. The statistical package used was
Minitab. The differences were treated signiﬁcant if the P value ≤
0.05.
2.2. Chronic hypoxic rats
All procedures under this project have been performed under the
UK Animals (Scientiﬁc Procedures) Act 1986. Male Sprague–Dawley
rats of body weight 125–150 g were placed in a hypobaric chamber at
600 millibar pressure for a 14 day period. Animals in the hypobaric
chamber had pulmonary hypertension (mean pulmonary arterial
pressures in hypoxic rats 20.1±0.9 mm Hg; in normoxic rats 11.9±
0.9 mm Hg; P≤0.0001; n=8–10) and right ventricular hypertrophy
(ratio of right ventricular weight/weight of the left ventricle+septum
in the hypoxic rats 0.41±0.007 compared to the normoxic control
rats 0.26±0.004, P≤0.0001; n=31). At the end of this period the
rats were deeply anaesthetized with sodium pentobarbitone (2 ml/kg
intraperitoneal injection) and ventilated. The thorax was opened and
the pulmonary artery was cannulated and perfused with heparinized
Krebs–Henseleit solution (119 mM NaCl, 25 mM NaHCO3, 11 mM
glucose, 4.6 mM KCl, 1.2 mM MgCl2, 1.2 mM KH2PO4 and 2.5 mM
CaCl2 with 100 units/ml heparin, 4% albumin and 1 mM ﬂurbiprofen)
in a recirculating circuit. Perfusion was constant ﬂow with measure-
ment of perfusion pressure at the pulmonary artery cannula. A
cannula was inserted into the trachea for ventilation of the lungs
with either a normoxic (20% O2, 5% CO2, and 75% N2) or hypoxic (0%
O2, 5% CO2, and 95% N2) atmosphere.
Slight tone was induced in the perfused lungs using the throm-
boxane A2mimetic, 9,11-dideoxy-11α, 9α-epoxymethanoprostaglan-
din F2α (U46619, 3×10−5 M) given as a bolus dose to the perfusion
circuit. Relaxation was induced using the endothelium-dependent
vasorelaxant, calcium ionophore A23197, added in increasing doses.
During the course of the experiments no visible lung oedema was
observed and this was conﬁrmed by measuring the weights of the
lungs at the end of every experiment.
Drug-treated rats received ADDP during the period that they were
in the hypoxic chamber. ADDP was administered to the rats via
subcutaneous injections to give a dose of 14.1 mg/kg/day as daily
injections in the morning for both the hypertensive and the
normotensive groups of rats. The ADDP solution for injection
contained ADDP 100 mM ADDP dissolved in dimethyl sulfoxide. The
subcutaneous site of injection was in the neck region or on the back of
the rats avoiding the spine, and was changed every day in order to
prevent soreness at the site of injection.
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Immunohistochemistry was used to perform eNOS staining on
the lung sections as previously described (Grant et al., 2006). Lungs
from normoxic and chronically hypoxic rats, which have been treated
with or without ADDP were perfused with formalin, dehydrated,
and embedded in parafﬁn wax and 3 μm sections were cut. The lung
sections were rehydrated, treated with 0.3% H2O2 for 10 min to block
endogenous peroxidase activity and then heated by microwave to
expose the antigens. The sections were blocked with 20% normal goat
serum then incubated for 1 h with mouse monoclonal anti-human
eNOS primary antibody (1:2000) (BD Transduction Laboratories).
Sections were then treated with biotinylated secondary antibody
(30 min) followed by avidin-labelled horseradish-peroxidase
(40 min) and then 0.5% diaminobenzidine tetrahydrochloride acti-
vated with 30% H2O2 (10 min). The sections were counterstained with
haematoxylin. The slides were coded so that the investigator was not
aware of their identity during scoring. Sections were viewed under
400× magniﬁcation allocating intensity scores from 0–3 for each
section, where 0 represents no staining, 1 is mild or uneven staining, 2
is moderate staining and 3 represents maximum staining observed
with the antibody at the highest level of eNOS expression encoun-
tered. Intermediate intensity levels gave scores of 0.5, 1.5 and 2.5. In
each staining run negative controls were included, where sections
were not treated with primary antibody.
The values are expressed as means±standard errors of means
(S.E.M.) where n=number of animals. Statistical tests were performed
using analysis of variance general linear model (repeated measures
design) to compare two cumulative dose–response curves generated
in two different tissues, using Minitab. Histological scores were com-
pared using Student's unpaired t-test. The differences were treated
signiﬁcant if the P value ≤ 0.05.
2.3. Drugs and solutions
BH4 stock solution was stored at −20 °C and minutes before the
addition into the bath a single aliquot was taken out, thawed and
diluted. Working solutions were kept on ice at all times when outside
and protected from light. Stock solutions of the ADDP and HMP
(2 mM) were dissolved in 2 M NH4OH. Further dilutions were made
with distilled water and these were stored at 4 °C.
BH4, DAHP and L-NAME were bought from Sigma Aldrich Ltd,
Poole, Dorset, UK; Spermine NONOate from Merck Biosciences Ltd,
Beeston, Nottingham, UK; Ham's medium (Nutrient mixture HAM F-
12) and Waymouth medium MB 752/1 with L-glutamine were from
Invitrogen Ltd, Paisley, UK. ADDP and HMP were synthesised as
previously described (Suckling et al., 2008).
3. Results
3.1. Artery ring experiments
Both analogues of tetrahydrobiopterin produced dose-dependent
relaxation in pulmonary arteries treated with DAHP. ADDP (6-acetyl-
7,7-dimethyl-7,8-dihydropterin ) produced a maximum relaxation
at 0.3 μMof 28.1±4.3% and HMP (6-hydroxymethyl pterin) produced
a maximal relaxation at 0.3 μM of 18.8±10.4% (Fig. 1A, B). ADDP-
induced and HMP-induced relaxation were completely abolished
following preincubation with the NO synthase inhibitor, L-NAME
(300 μM) (Fig. 1A, B). However, in pulmonary artery rings that had
not been treated with DAHP, ADDP had no signiﬁcant effect, and the
relaxation generated by HMP was reduced (Fig. 1C, D).
Relaxation induced by the NO donor spermine NONOate was
unaltered by co-administration of either ADDP 0.3 μM or HMP 0.3 μM
in DAHP-pretreated artery rings (Fig. 2A, B). Similarly, incubation
with either ADDP or HMP (0.3 μM) did not have any effect on
endothelium-dependent vasorelaxation caused by carbachol in pul-
monary arteries pretreated with DAHP (Fig. 2C, D).
Contrary to the effects of the BH4 analogues ADDP and HMP, BH4
itself did not produce any signiﬁcant relaxation over a concentration
range of 10−8–10−5 M. No relaxation occurred in pulmonary arteries,
whether they had been pretreated with DAHP or not (Fig. 3A, B).
Indeed the highest concentration of BH4 induced a signiﬁcant con-
traction (Fig. 3A, B). In addition, in pulmonary arteries we found that
incubation with BH4 (100 μM) resulted in reduction of potency of
carbachol-induced relaxation at the initial concentrations without
altering the maximum relaxation obtained (Fig. 4A). The superoxide
scavenger, MnTMPyP 30 μMdid not prevent the contraction produced
by BH4 in pulmonary arteries (Fig. 4B).
Fig. 1. Effects of ADDP and HMP in DAHP-treated (A, B respectively) and untreated (C, D respectively) phenylephrine-precontracted pulmonary arteries (■=ADDP, □=ADDP+
L-NAME, ▲=HMP, Δ=HMP+L-NAME, x=vehicle control). Values are expressed as means+S.E.M. and n=5–9. *P≤0.05 or **P≤0.01 versus solvent control and ++P≤0.01 or
+++P≤0.001 versus L-NAME.
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3.2. Effects of treatment with ADDP on relaxation responses of calcium
ionophore in isolated perfused lungs
Following preconstriction with U46619, responses to the endo-
thelium-dependent vasorelaxant, calcium ionophore A23187, were
measured in perfused lungs from pulmonary hypertensive and
normotensive rats. Calcium ionophore A23187 completely relaxed
the pulmonary circulation of both pulmonary hypertensive and nor-
motensive rats. Chronic treatment of the rats with ADDP potentiated
pulmonary relaxation in response to A23187 both in pulmonary
hypertensive and in normotensive rats (Fig. 5A, B). Calculation of the
EC50 values conﬁrmed the potentiation effect of ADDP treatment in
Fig. 2. Vasorelaxant effects of spermine NONOate (A, B) and carbachol (C, D) in pulmonary arteries pretreated with DAHP and precontracted with phenylephrine. Spermine NONOate
or carbachol was added in the presence of ADDP 0.3 μM (■) or HMP 0.3 μM (▲) or vehicle (x). Values are expressed as means+S.E.M. and n=4–6.
Fig. 3. Effects of BH4 in DAHP-pretreated (A) and untreated (B) and phenylephrine-
precontracted pulmonary arteries (●=BH4 and○=time control. Values are expressed
as means+S.E.M. and n=7–11. **P≤0.01 versus time control.
Fig. 4. (A) Vasorelaxant effects of carbachol in the presence or absence of BH4 in
phenylephrine-precontracted pulmonary arteries (○=carbacholalone,▬=carbachol+
BH4). (B) Effects of BH4 on phenylephrine-precontracted pulmonary arteries in the presence
ofMnTmPyP 30 μM.●=BH4, x=BH4+MnTMPyP. Values are expressed asmeans+S.E.M.
and n=6. **P≤0.01 carbachol versus carbachol+BH4.
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both normoxic as well as hypoxic rat lungs as shown by the signiﬁcant
left-ward shift in the calcium ionophore A23187 dose–response
curves generated in the ADDP-treated rat lungs compared to the
untreated rat lungs (1.1±0.1×10−6 M versus 1.5±0.1×10−6 M in
normoxic ADDP-treated and untreated rats respectively, P value ≤
0.05, n=8–20; 1.2±0.2×10−6 M versus 1.7±0.1×10−6 M in hyp-
oxic ADDP-treated and untreated rats respectively, P value ≤ 0.05,
n=8–20).
3.3. Effects of treatment with ADDP on eNOS expression
Lung samples from untreated and ADDP-treated rats were stained
for eNOS immunoreactivity. eNOS immunoreactivity was present
throughout the vascular endothelium of small and large pulmonary
arteries. Quantitative staining intensity analysis showed that eNOS
immunostaining was signiﬁcantly higher in the pulmonary hyper-
tensive rat lungs when compared to the normotensive controls.
Normotensive rats that had been treated with ADDP had signiﬁcantly
higher eNOS expression when compared to the normotensive rats
that had received vehicle. In pulmonary hypertensive rats, eNOS
expression was already at a high level and was not further increased
by treatment with ADDP (Fig. 6).
4. Discussion
In the search for improved molecules that can reverse BH4
deﬁciency, sepiapterin has been administered to diabetic rats
(Pannirselvam et al., 2003), however it requires conversion by
sepiapterin reductase within cells. 5-Methylfolate has been found to
improve endothelium function in rats that were depleted of BH4
(Hyndman et al., 2002), however it is not clear whether this relatively
bulky molecule can bind stably to the pterin binding site on eNOS.
Numerous analogues of BH4 have been synthesised, however where
these have been tested they inhibit, not stimulate, eNOS (Bömmel
et al., 1998; Fitzal et al., 2002; Fröhlich et al., 1999; Gibraeil et al.,
2000; Gorren et al., 2000).
Our results show that the BH4 analogues, ADDP and HMP, cause
vasorelaxation in pulmonary arteries that have been depleted of
endogenous levels of BH4 by incubation with DAHP. ADDP-induced
and HMP-induced relaxation was completely abolished by incubation
with L-NAME indicating that relaxation is due to NO formation from
Fig. 5. Vasorelaxant responses of calcium ionophore A23187 in U46619-precontracted
(A) chronic hypoxic pulmonary hypertensive and (B) normotensive control rat lungs.
(A) Chronic hypoxic rats were ADDP-treated (■) or untreated (x). (B) Matched control
normotensive rats were ADDP-treated (□) or untreated (w). Rats were treated with
ADDP 14.1 mg/kg/day s.c. (□,■). Values are expressed as means±S.E.M. and n=8–20.
**P value≤0.01 comparing ADDP-treated with respective untreated groups.
Fig. 6. Micrographs of small pulmonary arteries from lungs of rats treated with ADDP
with immunohistochemistry for eNOS. (A) Pulmonary hypertensive rat, ×40 objective
(B) normotensive rat, ×40 objective. (C) Quantitative measurement of eNOS staining
in endothelial cells of small pulmonary arteries in control and ADDP-treated nor-
moxic and chronic hypoxic rats. Values are expressed as means±S.E.M. and n=4–10.
**P value≤0.01 chronic hypoxic versus normoxic.
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NOS. This is consistent with the generation of NO by ADDP
demonstrated in cultured cells (Suckling et al., 2008). Since ADDP
and HMP did not modify vasorelaxation induced by the NO donor
spermine NONOate, the analogues are not acting via potentiation of
NO already present within the artery environment. Since ADDP and
HMP did not cause any vasorelaxation when arteries retained their
normal BH4 content, it is likely that ADDP and HMP cannot displace
BH4 from NOS but may substitute for BH4 when the pterin site
is unoccupied. It is likely that the two analogues of BH4 in higher
oxidation states undergo an intracellular reduction reaction to form
the active molecule that makes functionally competent NOS (Suckling
et al., 2008).
Carbachol was still able to induce a full relaxation of pulmonary
artery rings after depletion of BH4 with DAHP, and treatment with
ADDP did not signiﬁcantly change the carbachol concentration–
response curve. The explanation is probably that stimulation of
muscarinic receptors gives a powerful activation of eNOS that is
supramaximal. Certainly NO formation exceeds the amount required
for maximal relaxation in rat mesenteric artery (Simonsen et al.,
1999). Thus even though eNOS is impaired a signiﬁcant NO generating
capacity remains. This implies that the DAHP treatment has not fully
eliminated BH4 from the vascular wall.
BH4 produced no relaxation in pulmonary arteries evenwhen their
endogenous BH4 content had been depleted, and in fact produced
signiﬁcant contraction in pulmonary arteries at the higher concentra-
tions studied. The effects of BH4 were demonstrated for the ﬁrst
time in the current work in isolated pulmonary arteries. In addition to
the direct contractile effect of BH4, incubation with BH4 resulted in
reduction in the potency of endothelium-dependent vasorelaxation
with carbachol in pulmonary arteries. The contraction seen with
direct administration of BH4 was consistent with what has been
observed in the dog basilar artery (Kinoshita and Katusic, 1996) and in
aortic rings (Yang et al., 2003). In oxygenated buffer at physiological
pH, BH4 undergoes autoxidation, which can generate superoxide
(Blair and Pearson 1974; Kirsch et al., 2003; Nishikimi 1975). How-
ever, incubation with the cell-permeable SOD mimetic, MnTMPyP,
had no effect on the contraction seen with BH4 in pulmonary arteries
in our study. This indicates that the BH4-induced contraction is
unlikely to involve superoxide formation.
In ADDP-treated rats there was signiﬁcant potentiation of calcium
ionophore A23187-induced relaxation in both normoxic and hypoxic
rat lungs when compared to the respective normoxic and hypoxic rat
lungs of the untreated group. This indicates that chronic treatment
with ADDP resulted in improvement of NO-mediated pulmonary
artery dilation. On chronic administration this improvement in
pulmonary endothelial function was found not only in the pulmonary
hypertensive rats but also in normotensive rats. In normotensive rats,
there was enhanced expression of eNOS in the pulmonary vascular
endothelium, which may explain the improved response to calcium
ionophore A23187 found in vivo despite the carbachol response in
vitro being unchanged. Since pulmonary hypertension raised expres-
sion of eNOS in the pulmonary vascular endothelium to a high level, it
is unsurprising that ADDP treatment was unable to further increase
eNOS expression in chronically hypoxic rats. In pulmonary hyperten-
sion, eNOS expression is upregulated in pulmonary arteries, although
the output of NO is diminished due to uncoupling of NOS (Demiryürek
et al., 2000; Weerackody et al., 2009). Thus pulmonary hypertension
is able to develop despite the increased eNOS protein present in
the pulmonary circulation. Nevertheless in the chronically hypoxic
rat ADDP administration did improve calcium ionophore A23187-
induced relaxation. This may indicate improved performance of eNOS
in the pulmonary vascular endothelium in pulmonary hypertension.
In conclusion, this study identiﬁes two analogues of BH4, which
can act as oxidatively stable alternatives to BH4 in causing NO-
mediated vasorelaxation. Treatment with ADDP improved endothe-
lium-dependent vasorelaxation in isolated perfused lungs from both
normoxic and hypoxic rats and increased eNOS expression in these
rats.
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